Pathological oxygen deprivation inhibits prolyl hydroxylase (PHD) activity and stimulates a protective cellular oxygen-sensing response in part through the stabilization and activation of the Hypoxia Inducible Factor (HIF) 1α transcription factor. The present investigation tested the therapeutic potential of enhanced activation of oxygen-sensing pathways by competitive pharmacologic PHD inhibition after stroke, hypothesizing that post-ischemic PHD inhibition would reduce neuronal cell death and require the activation of HIF-1α. The PHD inhibitor dimethyloxaloylglycine (DMOG, 100 μM) reduced cell death by oxygen glucose deprivation (OGD), an in vitro model of ischemia, and the protection required HIF-1α. In vivo, DMOG (50 mg/kg, i.p.) administered 30 or 60 min after distal occlusion of the middle cerebral artery (MCA) in mice enhanced the activation of HIF-1α protein, enhanced transcription of the HIF-regulated genes vascular endothelial growth factor, erythropoietin, endothelial nitric oxide synthase, and pyruvate dehydrogenase kinase-1, reduced ischemic infarct volume and activation of the pro-apoptotic caspase-3 protein, reduced behavioral deficits after stroke, and reduced the loss of local blood flow in the MCA territory after stroke. Inhibition of HIF-1α in vivo by Digoxin or Acriflavine abrogated the infarct sparing properties of DMOG. These data suggest that supplemental activation of oxygen-sensing pathways after stroke may provide a clinically applicable intervention for the promotion of neurovascular cell survival after ischemia.
Introduction
Ischemic stroke is the third leading cause of human death and disability in the United States (American Heart Association, 2008 Update). Development of an effective therapy for acute ischemic attack is an urgent issue in basic and preclinical research. Ischemic stroke is characterized by a vascular occlusion in the brain that reduces tissue perfusion and starves neurons of nutrients and oxygen supply causing rapid depolarization of neurons, and initiating a cascade of events that lead to acute necrotic, delayed apoptotic, and excitotoxic cell death (Lipton, 1999) .
The evolutionarily conserved cellular pathway that detects and reacts to varying tissue oxygen availability is a potent endogenous protective mechanism against hypoxic/ischemic injury. Key elements in this homeostatic pathway are the prolyl hydroxylase (PHD) oxygensensing enzymes and the hypoxia inducible factor (HIF) transcription factor (Jiang et al., 1996; Wang and Semenza, 1993c, 1995) . Under normal oxygen availability, PHDs constitutively hydroxylate HIF-1α on two conserved proline residues (Epstein et al., 2001) , mediating the interaction of HIF-1α with the E-3 ubiquitin ligase von Hippel Lindau (Ivan et al., 2001; Jaakkola et al., 2001) . Therefore, under normal oxygen tension, hydroxylated HIF-1α is poly-ubiquitinated and targeted for proteasomal degradation (Sutter et al., 2000) . When HIF-1α is unhydroxylated, the stable protein accumulates, and translocates to the nucleus. HIF-1α and heterodimeric partner HIF-1ß, activate gene transcription at hypoxia-responsive elements including genes involved in promotion of cell survival (Zaman et al., 1999) , angiogenesis (Forsythe et al., 1996; Palmer et al., 1998) , and anaerobic metabolism (Semenza, 1994) . HIF-1-regulated genes include the vascular endothelial growth factor (VEGF) (Forsythe et al., 1996) , endothelial nitric oxide synthase (eNOS) (Coulet et al., 2003) , erythropoietin (EPO) (Wang and Semenza, 1993b) , and pyruvate dehydrogenase kinases 1 and 4 (Aragones et al., 2008; Kim et al., 2006; Papandreou et al., 2006) .
PHDs require oxygen, iron, 2-oxoglutarate, and ascorbate for the hydroxylation reaction and therefore may be inhibited by depletion or competition of these factors leading to HIF-1α stabilization (Bruick and McKnight, 2001; Siddiq et al., 2005; Wang and Semenza, 1993b) . Previous studies have indicated that preconditioning of neuronal cultures with PHD inhibitors induces HIF-1α and a corresponding protective response that renders cells resistant to subsequent oxidative cell stress (Siddiq et al., 2005) or nerve growth factor withdrawal (Lomb et al., 2007 
Contents lists available at SciVerse ScienceDirect
Neurobiology of Disease j o u r n a l h o m e p a g e : w w w . e l s e v i e r . c o m / l o c a t e / y n b d i
